Eli Lilly announced the positive results of Phase 3 clinical trial of its drug, lebrikizumab, in treating atopic dermatitis. There was a significant improvement in face dermatitis and hand dermatitis, which are the most visible parts of the body.
Lilly presented the ADvocate 1, ADvocate 2 studies, and ADhere studies demonstrating the improvements or clearance of face or hand dermatitis. Skin improvements are demonstrated with or without the use of corticosteroids.
ADvocate 1 and ADvocate 2 are 52-week, placebo-controlled studies, and ADhere is a 16-week placebo-controlled study in patients with moderate-to-severe atopic dermatitis.
In ADvocate 1 and ADvocate 2 studies, at 52 weeks, 80% of patients maintained EASI-75 response after achieving EASI-75 at Week 16.
Lebrikizumab is a monoclonal antibody that targets interleukin-13 (IL-13), a protein that plays a vital role in developing and progressing atopic dermatitis.